The latest information

Chemical engineer Katerina Leonida embarks on a PhD covering the DC8 project within the GEne Therapy INnovation training network (GET-IN)

Well-equipped and integrated R&D labs for custom bioprocess development from concept to scalable production

Pascale Berthet sharpens Antleron's go-to-market strategy, bolstering its growth trajectory in pharma and biotech

Factories of the future - a far dream or close reality?

Antleron & Novasign digital twin approach for scalable cell & gene therapy bioprocess development showcased at ESACT 2024

Antleron CEO Jan Schrooten recognized for his scientific work

David Nauwelaers strengthens the development of Antleron’s manufacturing capabilities enabling custom bioprocess scaling and GMP translation

Britt Van Ballaer develops bioreactor systems in support of scalable bioprocesses and next generation therapies

Digital twins fast-track bioprocess development

Anaïs Schaschkow presents in vitro bone model at Organoid@KU Leuven Symposium

Bayesian optimization accelerates cell therapy process development

Our Antleron Fellows: a vibrant, multidisciplinary team of scientists

Antleron and Tuatara Dx team up to revolutionize point-of-need diagnostics

Trends Gazellen 2024 nomination for Antleron

Antleron joins Flemish-Brabant advanced therapy delegation to Heidelberg-Mannheim ecosystem

Belgians send miniature heart into space for ageing research

Biodevice-CRO showcase article on BioVox

Antleron interns taking part in innovative ATMP developments

Showcasing our collaborative Biodevice-CRO offering at Knowledge for Growth 2023 in Antwerp

Dieter Hauwaerts brings strategic and operational ATMP excellence to the Antleron team